3rd May 2024
- 0 comments
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital. Series A financing to advance clinical development of lead candidate RLS-1496 into Phase 1 studies this year in chronic atopic dermatitis and chronic psoriasis. Financing will also advance respiratory program, recipient of a substantial CIRM grant last year, to development candidate nomination for idiopathic pulmonary fibrosis.
...Register / Login now to read full story
In order to read the full story we need you to be registered with us, please click the links below to login or register.
Back to Homepage